<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04086290</url>
  </required_header>
  <id_info>
    <org_study_id>Oligomet_DK</org_study_id>
    <nct_id>NCT04086290</nct_id>
  </id_info>
  <brief_title>National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients</brief_title>
  <acronym>Oligomet_DK</acronym>
  <official_title>Oligomet-DK. National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Busch Østergren</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open label phase 2 clinical trial assessing safety, complications and
      feasibility of radical prostatectomy (RARP) plus local stereotactic body radiotherapy (SBRT)
      to bone metastases in combination with short-term medical castration to a select population
      of prostate cancer patients with oligometastatic disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">October 2028</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of men with Grade ≥ 3 adverse events the first year</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of men with Grade ≥ 3 adverse events the first year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of men achieving prostatic specific antigen (PSA) &lt; 0.1 ng/ml</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of men achieving prostatic specific antigen (PSA) &lt; 0.1 ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of radical prostatectomy in the oligometastatic setting</measure>
    <time_frame>1 year</time_frame>
    <description>Feasibility of radical prostatectomy in the oligometastatic setting measured as number of patients who successfully undergo radical prostatectomy with pelvic lymphnode disection and 30 days (post-operative) morbidity according to the Clavian Dindo Classification.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to castrate resistance (TCR)</measure>
    <time_frame>5 yrs</time_frame>
    <description>Time to castrate resistance (TCR) measured from the primary initiation of ADT to Castrate Resistant Prostate Cancer (CRPC) defined as: Three consecutive rises in PSA one week apart resulting in two 50% increases over the nadir, with PSA &gt; 1 ng/mL or the appearance of two or more new bone lesions on bone scan or enlargement of a soft tissue lesion using RECIST. At the same time serum testosterone is &lt;50ng/dL (&lt;1.70 nnmol/L).</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life (FACT-P-DK)</measure>
    <time_frame>5 yrs</time_frame>
    <description>Changes in Quality of life assessed by the questionaire FACT-P-DK and calculated using the FACT-P Scoring Guidelines (Version 4). The following scores will be evaluated:
FACT-P Trial Outcome Index (TOI). Score range: 0-104 (The higher score the better). Combines the subscales &quot;Physical well-being&quot;, &quot;Functional Well-being&quot; and &quot;Prostate Cancer Subscale&quot;
FACT-G total score. Score range: 0-108 (the higher score the better QoL). Combines the subscales: &quot;Physical well-being&quot;, &quot;Social well-being&quot;, &quot;Emotional well-being&quot; and &quot;Functional well-being&quot;.
FACT-P total score. Score range: 0-156 (the higher score the better QoL). Combines the subscales: &quot;Physical well-being&quot;, &quot;Social well-being&quot;, &quot;Emotional well-being&quot;, &quot;Prostate Cancer Subscale&quot; and &quot;Functional well-being&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Interventions on lower or upper urinary tract</measure>
    <time_frame>5 yrs</time_frame>
    <description>Number of participants undergoing with interventions on lower or upper urinary tract, i.e.:
Bladder catheter
Ureteric stent
Nephrostomy
Transurethral resection of the prostate (TURP) or related procedure</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>RARP + SBRT + ADT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radical prostatectomy + extended pelvic lymph node dissection according to EAU guidelines followed by stereotactic body radiotherapy to osseous lesions with six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RARP</intervention_name>
    <description>Radical prostatectomy + extended pelvic lymph node dissection</description>
    <arm_group_label>RARP + SBRT + ADT</arm_group_label>
    <other_name>Robot assisted Radical Prostatectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Stereotactic body radiotherapy to osseous lesions</description>
    <arm_group_label>RARP + SBRT + ADT</arm_group_label>
    <other_name>Stereotactic body radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADT</intervention_name>
    <description>six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.</description>
    <arm_group_label>RARP + SBRT + ADT</arm_group_label>
    <other_name>Androgen deprivation therpay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older and willing and able to provide informed consent;

          2. Stage cT1 ≤ cT3b, Clinical resectable

          3. Gleason score ≥ 6

          4. M1

               1. ≤ 3 bone metastases localized to the spine, pelvis or humeral/femoral bones as
                  evaluated by 68Ga-PSMA PET/CT and magnetic resonance imaging (MRi)

               2. Absence of PSMA uptake in retroperitoneal lymph nodes, (outside the anatomical
                  region of extended pelvic lymph node dissection as described in the European
                  Association of Urology (EAU) guidelines.

               3. No visceral metastasis

               4. Metastases suitable for stereotactic body radiotherapy

               5. Non symptomatic bone lesions

          5. Eligible for surgery

        Exclusion Criteria:

          1. Prior curative intended treatment for prostate cancer

          2. Prior androgen deprivation therapy (ADT)

          3. History of another invasive cancer within 3 years of screening, with the exception of
             fully treated cancers with a remote probability of recurrence. The medical monitor and
             investigator must agree that the possibility of recurrence is remote for exceptions.

          4. Eastern Cooperative Oncology Group (ECOG) Performance Status &gt; 1

          5. Evaluated not able to fulfil the study protocol.

          6. Contraindications against MRI
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter B Østergren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev and Gentofte Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter B Østergren, MD</last_name>
    <phone>+4538681505</phone>
    <email>peter.busch.oestergren@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herlev and Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter B Østergren, MD</last_name>
      <phone>+4538681505</phone>
    </contact>
    <investigator>
      <last_name>Peter B Østergren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Peter Busch Østergren</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <keyword>prostatectomy</keyword>
  <keyword>androgen deprivation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

